LYRIC BIO

At Lyric Bio we're using proven tissue engineering technology to unlock biomanufacturing in supply restricted donor derived therapeutic markets. We're looking forward to taking on IvIg/ScIg production, a $15B global market with shortages that impact patient access and health.

We are delighted to announce that Dr. Erin Stephens is joining Lyric Bio, Inc. as our founding Scientific Director. Dr. Stephens was instrumental in developing bioengineered human tissues at Prellis Biologics, including human lymph node organoids which are the basis of the Prellis EXIS platform. In recent years Erin has developed deep expertise in CAR-T manufacturing processes and has over a decade of experience implementing rigorous quality management systems instrumental in linking the fields of cellular immunotherapy and biomanufacturing. Welcome to the team Erin

Grace Otos, a second year Biochem major at CalTech took a non-traditional internship this summer and helped launch a new start-up company Lyric Bio. Read her Founders interview here and learn more about the vision of the founders behind Lyric Bio and why they've teamed up to tackle a long-ignored area of pharmaceutical manufacturing.

Subscribe to the Lyric Bio Substack (https://lnkd.in/gcc6zxax) to learn more about our vision for next-generation manufacturing of 'Complex Therapeutics' and why we believe another #biotechnology revolution can't happen until we solve this problem. #biotech #biomanufacturing #ivig #scig #startup

Have you ever considered the core technology that enabled the Biotechnology revolution? We're delighted to announce the formation and launch of LYRIC BIO, founded by two experienced biotech founders who identified a significant common gap across multiple life-saving medicines. Follow us as we develop next-generation manufacturing to address the therapeutics left behind in the biotech revolution. Read more at www.LyricBio.com